12-month seed funding to identify novel therapeutic targets and rational combinations in head & neck cancer using genomics, immune profiling, mechanistic studies, human tissues (preferred), and/or animal models. Collaborative, translational projects are encouraged.
Eligibility criteria:
-
Applicants must reside in the U.S. or Canada and be AHNS members in good standing.
-
Eligible roles: medical students, residents, fellows, graduate students, PhDs, and faculty up to associate professor.
-
Trainees must have appropriate faculty mentorship.
-
Not eligible if the same project is already funded by a private/federal agency; if multiple awards are offered for the same project, only one may be accepted.
Funding details:
-
Amount: up to $15,000 (12 months, non-renewable).
-
PI salary not allowed; allowable costs include research personnel, consultant/statistical support, software/hardware, animals, lab supplies/services, and publication costs (excluding reprints).
-
Indirect costs: up to 10% maximum; total costs may not exceed $15,000.
-
Equipment/supplies become property of the recipient institution.
Deadline:
-
Letter of Intent due: December 15, 2025.
-
Full application due: January 15, 2026 (11:59 p.m. ET).
-
Notification: June 2026; award may start as early as July 1, 2026, and no later than January 1, 2027.
Where to go for further information:
- Applications must be submitted via ProposalCentral.
- Inquiries: Loren Hamilton, [email protected].